A novel drug named Dasatinib is a highly potent ATP-competitive orally active dual Src/Abl kinase inhibitor with anti-proliferative activity against solid tumors and CML (chronic myeloid leukaemia) cell lines. This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.